Mae'r Cyd-bwyllgor hefyd wedi nodi yn ystod y rhaglen hon, fod modd defnyddio brechlyn COVID-19 VidPrevtyn Beta a gafodd ei ddatblygu gan Sanofi/GSK a'i gymeradwyo gan yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) ym mis Rhagfyr, ochr yn ochr â'r brechlynnau mRNA diweddaraf a ddatblygwyd gan Pfizer a Moderna. Mewn treialon clinigol, roedd canlyniadau brechlyn Sanofi/GSK yn gymaradwy â chanlyniadau’r brechlynnau mRNA COVID-19. Mae'r Cyd-bwyllgor wedi argymell y brechlyn ar gyfer pobl dros 75 oed, ac mae’n addas i bobl nad ydynt yn gallu goddef brechlynnau mRNA. Nid oes angen sicrhau amodau storio mor llym ar gyfer y brechlyn hwn o'i gymharu â’r brechlynnau mRNA COVID-19, sy'n golygu bod modd gweithredu mewn ffordd fwy hyblyg wrth ei ddefnyddio. Mae'n bosibl y bydd hyn yn ei gwneud yn haws i bobl gael eu brechu.
The Committee has also advised that the VidPrevtyn Beta COVID-19 vaccine developed by Sanofi/GSK and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in December, can be deployed alongside the very latest mRNA vaccines by Pfizer and Moderna during this programme. In clinical trials the Sanofi/GSK vaccine had results comparable to the COVID-19 mRNA vaccines and has been recommended by the JCVI for people over 75.  This vaccine, which is suitable for those intolerant of mRNA vaccines, also has less stringent storage conditions, as compared to the mRNA COVID-19 vaccines, which will allow for greater operational flexibility in its use and may improve access to vaccination.